leisure time -WSS

leisure time

author：comprehensive 2025-09-05 11:19:27 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Trump's false claims about Georgia's 2020 election long debunked

Wikipedia

knowledge

WSS

Baltimore teen accused of firing into crowd during block party mass shooting

Francis Collins on trust in science and how Covid communications failed

Evacuations in place as 3 wildfires burn in eastern Washington state

Think you might have Covid

ProMED sees offers of support, but its future remains unclear

Elizabeth Holmes banned from government health programs

knowledge

leisure time

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Lung cancer is America's deadliest cancer. Yet so few get screened

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New definition of a human embryo proposed amid rapid advances

Medical records are filled with copy

The surgeon had a dilemma only a Nazi medical text could resolve

State Dept. review finds Biden bears some blame for Afghanistan failures

Eye stem cell transplant could help restore vision in injured people

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA approves first treatment for ultra

knowledge

Think you might have Covid

Prior authorization will have to move faster under new Biden rule

Listen: Racing for gene therapy & a pioneering approval

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Hilary expected to bring catastrophic, life

FDA approves first treatment for ultra

Wikipedia

knowledge

entertainment

hotspot